Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes.
about
Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II studyClinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cellsRecent advance in antigen-specific immunotherapy for acute myeloid leukemiaPreferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignanciesNatural and pharmacological regulation of telomeraseTelomerase as a therapeutic target for malignant gliomas.Telomerase as a universal tumor-associated antigen for cancer immunotherapy.Telomeres and telomerase in hematologic neoplasia.T-cell therapy of leukemia.Adoptive cellular therapy: a therapeutic reality?Telomerase as a tumor-associated antigen for cancer immunotherapyStrategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantationHigh vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.Antigen-specific cellular immunotherapy of leukemia.Gene therapy and immunotherapy of prostate cancer: adenoviral-based strategies.Telomerase-based immunotherapy of cancer.Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.A review of vaccine clinical trials for non-small cell lung cancer.Telomerase immunity from bench to bedside: round one.Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.Prospects and challenges of building a cancer vaccine targeting telomeraseVaccine immunotherapy in breast cancer treatment: promising, but still early.In vitro activation of hTERT-specific T cell responses in lung cancer patients following chemotherapyDendritic cell-based immunotherapy for myeloid leukemias.The functioning antigens: beyond just as the immunological targets.Application of adoptive T-cell therapy using tumor antigen-specific T-cell receptor gene transfer for the treatment of human leukemia.Targeting telomerase in hematologic malignancy.Dendritic-cell vaccination for prostate cancer.Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer.Vaccines as consolidation therapy for myeloid leukemia.Is telomerase a viable target in cancer?Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia.Identification of an epitope derived from CML66, a novel tumor-associated antigen expressed broadly in human leukemia, recognized by human leukocyte antigen-A*2402-restricted cytotoxic T lymphocytes.Telomerase-pulsed dendritic cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma.Targeting cryptic epitope with modified antigen coupled to the surface of liposomes induces strong antitumor CD8 T-cell immune responses in vivo.Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes.Tumor-associated antigens for specific immunotherapy of prostate cancerP53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma.Combinatorial molecular marker assays of WT1, survivin, and TERT at initial diagnosis of adult acute myeloid leukemia.Ex vivo expanded telomerase-specific T cells are effective in an orthotopic mouse model for pancreatic adenocarcinoma.
P2860
Q24652592-1A51CCCB-C4F5-4031-B974-B6A9C3D8B8F0Q24804892-1F92F66F-7AE4-46FE-A678-5A4B2A0BCF9CQ27005765-66A418B8-B8CB-48C6-BAD0-3A555A59AE62Q28190215-9E252EA2-9620-4E25-AA31-7157A9FBAF56Q31038583-088AE3B8-9F9E-426F-8767-1FFF4663BF4DQ34535709-EEFEBA38-C17E-4569-8375-A161CB156DBFQ34535727-8634F89E-7D2B-40FF-9CF7-1DA3F65D2BA0Q34535734-56631D62-62BA-43E6-97C6-09A1226A485AQ34608658-439FC034-D02B-4815-BA04-00E2144E6658Q34875170-28E05516-7BFF-4FC8-BBE6-59EFABE232BBQ34878113-3D299365-50CD-4546-A043-4E3D407B0D5DQ35588845-C8BDA93D-23E5-43D0-8B65-69D1D10D0D5DQ35631830-189B0B65-FD8E-4179-B303-9A9044734BEEQ36240201-E51082D6-9B5B-49FB-862D-8EAA8BDD70F1Q36258513-A58CAEB5-37AE-4C1F-9C2B-B46664935DB2Q36600251-BD45D329-455A-4D9D-BE73-FF781511215CQ36662079-296F753E-C0B0-42EC-BEB3-291A45FD7501Q36675454-6DCBD8E3-59E3-49D6-8DEC-707A5C05283EQ36745749-A49627E7-9887-44B6-8B3E-D37270B67D86Q36793112-2A1CADF6-DCBC-4269-B6FA-892F88252770Q36918394-FEB76ECF-2EFC-423C-99CB-3BCA524FAD30Q36950477-C82302C8-4987-461A-8B8A-948F7FC62074Q36972928-8B8746DB-2916-4732-BFBF-1B8951128656Q37420778-6EB5CEA1-641A-4EB2-9CB3-8A8C48FDC689Q37483795-00A2DD5F-F03C-4A91-937B-B86CBD987FD2Q37747066-B222926F-86FF-40F8-8A8F-F6DFE7C2589CQ37750789-F920922C-6F7F-40CF-825B-7BBFB5BA0D88Q37773277-9F7D08F3-BE98-4D9B-AEA1-158AA2FB1CBDQ37785948-E19FBC85-2656-4FDA-9C68-A332BD13A57EQ37842342-FC252CA7-38CC-4532-A83E-6A5B26AEE7AFQ37908470-509AAB3F-190D-44E9-B366-B7C3187A1822Q38015123-1D3C47C4-5005-4B46-B148-14B19B96FBADQ39990744-CD5FC54C-C7C4-40B7-BFED-4AF4A038837BQ40361635-522D32C0-578E-41C8-99EC-6058379733FDQ40510640-4737C530-3B55-4BC3-B310-C65A6AFF8E95Q40750584-97E0512C-573A-427C-A63C-6A3DB1212AAEQ41977894-6213AD7F-CD58-4285-B957-1793D6D55519Q44269708-71353F83-35A4-4B94-B324-7E44DA5CD004Q50858158-6407C8A6-824F-4915-B4AA-45D95E194D33Q51890593-5D2AE438-A218-4521-ADC3-DA04970F8FAC
P2860
Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Identification of human telome ...... kemia cytotoxic T lymphocytes.
@en
type
label
Identification of human telome ...... kemia cytotoxic T lymphocytes.
@en
prefLabel
Identification of human telome ...... kemia cytotoxic T lymphocytes.
@en
P2093
P356
P1433
P1476
Identification of human telome ...... kemia cytotoxic T lymphocytes.
@en
P2093
P304
P356
10.1182/BLOOD.V97.9.2903
P407
P577
2001-05-01T00:00:00Z